On Thursday, the FDA granted accelerated approval to Novartis AG’s (NYSE:NVS) Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction of proteinuria in adults with primary ...

Novartis wins FDA approval for the label expansion of Fabhalta for a third indication ... FDA Approves Novartis Drug for Rare Kidney Disease Treatment March 21, 2025 — 02:10 pm EDT.

The approval Vanrafia marks the third drug approval for Novartis in its renal disease portfolio. Shares of Novartis have risen 16.5% year to date compared with the large cap pharmaceutical ...

This is Novartis’s third U.S. approval for its kidney disease portfolio in the last year. Fabhalta was granted FDA approval in C3 glomerulopathy in March 2025 and accelerated approval in IgAN in ...

Novartis NVS said it received accelerated approval from the U.S. Food and Drug Administration for a treatment to bring down elevated levels of protein in the urine of adults who have a rare kidney ...

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

Novartis NVS announced that the FDA has approved Fabhalta (iptacopan) for a third indication. The regulatory body approved the drug for the treatment of adults with C3 glomerulopathy (C3G) to ...

Novartis' Fabhalta (iptacopan) receives FDA accelerated approval as a first-in-class complement inhibitor for IgA nephropathy, reducing proteinuria in adults at risk of rapid disease progression.